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ScienceDirectThe complex biofilm architecture composed of extracellular
polymeric structures (EPS) provides a protective shield to
physiologically diverse bacterial cells immersed in its structure.
The evolutionary interplay between bacteria and their viruses
(phages) forced the latter ones to develop specific strategies to
overcome the biofilm defensive barriers and kill sessile cells.
Phages are equipped with a wide panel of enzyme-degrading
EPS macromolecules which together are powerful weapons to
combat biofilms. Antibiofilm performance can be achieved by
combining phages or phage-borne enzymes with other
antimicrobials such as antibiotics. Nevertheless, a variety of
enzymes encoded in phage genomes still need to be explored.
To advance in biofilm control strategies we must deepen the
understanding of the biofilm biology itself, as well as discover
and better exploit the unlimited antibacterial potential of
phages.
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Introduction
Biofilms are microbial communities adhering to surfaces
or formed on air–water interfaces. These communities are
encased in a dense self-produced polymeric and highly
hydrated matrix composed mainly of polysaccharides,
proteins, lipids, and extracellular DNA (eDNA) [1]. A
peculiar feature of the biofilm population is the fact that
cells are organized in specialized functions, ensuring the
adaptation of the community to diverse environments.www.sciencedirect.com On the other hand, the biofilm matrix confers the biofilm
extra protection against dehydration, starvation, and pre-
dation. For these reasons the biofilm phenotype has
greater adaptive advantages than the planktonic lifestyle
and therefore biofilms dominate in all habitats on Earth,
accounting for 80% of bacterial and archaeal cells in the
biosphere [2]. The competitive advantages of biofilms are
even more striking in adverse conditions, such as those
found in the human body. Human natural defences are
programmed to eliminate and prevent microbial coloni-
zation in internal organs and therefore invasive micro-
organisms need to display an arsenal of virulence factors
to be able to survive and proliferate. In these cases,
biofilm formation is an important strategy of microbial
survival. The protective effect of the biofilm matrix,
together with the resilience of the biofilm-associated
cells, contributes to high tolerance to antibiotics and
immune clearance. For this reason, the majority of bac-
terial chronic infections are caused by biofilms, with an
estimate of around 65% of all infections, according to the
Center for Disease Control (CDC), and 80% according to
the National Institutes of Health (NIH) [3]. Biofilms can
be formed on human tissues causing endocarditis, cystic
fibrosis, periodontitis, rhinosinusitis, osteomyelitis, non-
healing chronic wounds, meningitis, and kidney infec-
tions. Biofilms can also be formed on surfaces of biomed-
ical materials such as prostheses and implantable devices,
generating indwelling device-associated infections [4].
The negative implications of biofilms on human health
are tremendous and therefore effective methods to con-
trol biofilm-associated diseases are urgently needed.
Bacteriophages (phages) are the natural enemies of bac-
teria and as such, they can infect bacteria-forming bio-
films [5]. There is a growing scientific interest in phages
because of the need to discover and develop alternative,
or complementary, antimicrobial strategies to counteract
the increasing resistance to conventional antibiotic ther-
apy [6]. In particular, the interaction of phages with
biofilms has been subject to research in many scientific
publications, a number which has grown exponentially in
the last 10 years (source PubMed). The increased aware-
ness of the implications of biofilms on human health is
one of the reasons for this rising interest. Another reason is
the increasing amount of evidence that phages are more
efficient antibiofilm agents than traditional antibiotics.
Indeed, the majority of the scientific publications con-
cerning phages and biofilms report the successful appli-
cation of phages against mono and multispecies biofilms,
particularly formed by Escherichia coli, Pseudomonas aeru-
ginosa, and Staphylococcus aureus (also implicated in the
majority of biofilm-related infections). These studiesCurrent Opinion in Biotechnology 2021, 68:251–261
252 Nanobiotechnology - phage therapyhighlight the ability of phages to control biofilms but also
emphasize important concerns about their limitations and
suggest possible ways to improve phage effectiveness
[5,7,8–10,11,12].
In addition to phages, phage-encoded proteins have also
been widely exploited as powerful antibacterial weapons.
Phages use enzymes such as virion-associated peptido-
glycan hydrolases (VAPGHs), endolysins, and depoly-
merases to interact and kill their hosts. Some of these
enzymes are already utilized as recombinant proteins
offering a great antibacterial tool to effectively combat
biofilms. In this review, we discuss the existing research
regarding the biofilm as a complex structure, and the
probability of defeat by its natural bacterial enemy
(phages) and its enzymatic weapons. We also illustrate
here future perspectives on how phages and their evolu-
tionary strategies may help us design new antibiofilm
therapies.
Challenges associated with biofilm control
Biofilm eradication and prevention is a huge challenge for
current and future medicine, agriculture, the food indus-
try, animal husbandry, and a wide variety of human
activity. Biofilm has a complex architecture with inte-
grated biomolecules and mineral components called
extracellular polymeric structures (EPS), and biodiverse
microbial cells, all perfectly protected from external harsh
conditions, antibiotics, and the immune system response
(Figure 1). The thick EPS, partially hydrophobic or
hydrophilic, significantly limits the diffusion rate of che-
micals thereby reducing their local toxic concentration.
Moreover, biofilm conglomerate is organized in well
separated and protected microhabitats providing a vari-
ability of oxygen and nutrient conditions [13,14].
Diversity of biofilm-residing population
The structural organization of biofilm creates an oxygen
and nutrient gradient forcing embedded organisms to
adaptat to diverse conditions and thus to physiological
heterogeneity [1]. Bacteria may adopt different physiol-
ogies within the biofilm structure; we may find metaboli-
cally active, dormant, and persister physiological states.
The cross-talk of signal sensing regulatory networks such
as (i) two-component systems (TCS), (ii) diguanylate
cyclase systems (DGC), and (iii) quorum sensing (QS),
enable bacteria to have a dynamic response to environ-
mental changes [15,16]. The low availability of oxygen
and nutrients results in the arrest of bacterial metabolism-
transferring cells into dormant forms making them toler-
ant to many antibiotics and chemicals [17]. On the other
hand, hypoxia and nutrient depletion induce the switch-
ing to anaerobic respiration or a lag phase, changing the
bacterial susceptibility to particular drugs. Sessile cells
exhibit adaptive temporary tolerance to antibiotic expo-
sition called the persister phenotype. Moreover, the
physiological modification to biofilm conditions mightCurrent Opinion in Biotechnology 2021, 68:251–261 induce active resistance mechanisms such as antibiotic
inactivation, antibiotic target modification, or efflux pump
overproduction [18]. All the above complex aspects make




DNA forms long chains and is a perfect macromolecule to
build the spatial network for biofilm-embedded cells and
other matrix components.
Extracellular DNA (eDNA), as a negatively charged
structure, may interact with proteins localized on the cell
surface, such as outer membrane vesicles (OMVs), or
those immersed in the matrix. It may involve Type IV
pili (T4P), enzymes, innate immune elements, as well as
toxins. Moreover, the exopolysaccharides produced
intensively by sessile cells can colocalize with eDNA
chains giving the biofilm structure more strength. It is
worth mentioning that macromolecules providing a high
amount of negative charge protect the biofilm-living
bacteria from the toxic effect of metals or, vice versa,
accumulate desired ferric and calcium ions in the matrix
[19]. The eDNA can be delivered from enzymatically
lysed cells, OMVs transporting a genetic cargo, cell debris
left from phage propagation, or actively released DNA via
a T4SS-like system, as has been found in Haemophilus
influenzae [20]. The role of eDNA is not only limited to
structural purposes. It also serves in horizontal gene
transfer (HGT), driving the biodiversity and evolution
of biofilm-residing microbial populations. Some bacteria
like Vibrio cholerae can genetically benefit from close cell-
to-cell localization in the matrix milieu, and actively
collect foreign DNA from neighbouring bacteria via type
VI secretion system (T6SS) [21].
Polysaccharides
Polysaccharides are produced by all kinds of bacteria as an
element of cell surface structures — such as capsules,
lipopolysaccharide (LPS), peptidoglycan, or extracellular
products and also slime released into the biofilm matrix.
Those glycans serve bacteria in many ways — adhesion;
cell-to-cell interactions; evasion from the immune system
response; mimicking the macromolecules of the infected
host; protection against desiccation, and neutralizing toxic
compounds. Thanks to the formation of long chains,
sticky features, and being an easily accessible source of
energy, exopolysaccharides are perfect molecules for
biofilm structure [14]. Microorganisms mainly utilize
glucans, galactans, fructans, mannans or poly-N-acetyl-
glucosamine (PIA) to create biofilm EPS. P. aeruginosa
even produces three different polysaccharides (Psl, Pel,
alginate) promoting a sessile style of life. It was found that
Pel is composed of partially acetylated 1 ! 4 glycosidic
linkages of N-acetylgalactosamine and N-acetylglucosa-
mine and, as a cationic macromolecule, in the acidicwww.sciencedirect.com
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The complex biofilm structure formed on abiotic and biotic surfaces is encompassed by diverse microbial cells (planktonic, dormant, sessile)
immersed in extracellular polymeric structures (EPS). EPS causing oxygen and nutrient gradient, is composed of polysaccharides, eDNA, fiber-
forming proteins, glycan-binding proteins, outer membrane vesicles/membrane vesicles (OMVs/MVs), lipids, liquid-phage crystalline, and mineral
macromolecules, stabilizing biofilm conglomerate, and protecting embedded bacteria from external unfavourable conditions. The close cell-to-cell
interactions enable horizontal gene transfer (HGT) and quorum sensing (QS), as well as prophage induction driving the biodiversity and evolution of
biofilm-residing microbial populations (a). Phages are a self-producing weapon killing biofilm-living bacteria, as well as a source of already known
efficient enzymes degrading EPS macromolecules. The question mark refers to not yet discovered phage-based agents targeting biofilm
crystallines. Synthetic biology and deepened knowledge about biofilm biology would give new insight into future anti-biofilm perspectives (b).environment, interacts with negatively charged eDNA
increasing the physical durability of biofilm structure [22].
Several studies showed that exopolysaccharides increase
the biofilm tolerance to different antibiotics, but there are
no clues to the exact mechanism, as the ionic interactions
could be excluded in the case of uncharged P. aeruginosa
Psl. Contradictory results were also obtained for the drug
penetration ability within the biofilm milieu [23].
Proteins
An important element providing the structural stability of
formed biofilm is based on proteins which are able to
polymerize intohigher-orderstructures, calledamyloid-likewww.sciencedirect.com fibers or fiber-forming proteins. There are several examples
studied so far, including curli composed of CsgA units
produced by E. coli; TasA/TapA fibers formed by Bacillus
subtilis;PSM polymers found in S.aureus; FapB/FapC/FapE
nucleated and aggregated structures in Pseudomonas, and
more simple conglomerates built of self-assembled units,
Bap in S. aureus or P1 adhesin (AgI/II) in Streptococcus mutans
[24,25]. The main function of amyloid-like fibers is to form a
barrier protecting a bristling cell from physical interaction
with the exterior and preventing phage adsorption, or serum
complement deposition, on the cell wall surface. Protein
fibers together with the abundance of exopolysaccharides
also serve structural purposes. As the biofilm is a dynamicCurrent Opinion in Biotechnology 2021, 68:251–261
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amyloid-like fibers, both at the cell-dependent level and
a physical rate-limiting level, enabling the step-by-step
growth of biofilm structure [26]. An interesting example
of structural functioning protein is BslA produced by Bacil-
lus subtilis. This protein forms a hydrophobic protective
layer of dimers and tetramers when exposed to oxygen,
whereas it exists as a hydrophilic monomer in anoxic con-
ditions deep in the biofilm. This highlights yet another
mechanism of bacterial response to variation in redox con-
ditions and a fast adaptation to the biofilm style of life [27].
There is a panel of other surface structure proteins
including Type IV pili (T4P), flagella, lectins, glycan-
binding proteins, lectins, as well as polysaccharide-modi-
fication enzymes which all are engaged in the dynamic
steps of the biofilm attachment and maturation process.
Recent reports present the complex interactions of P.
aeruginosa outer-membrane protein OprF with other bio-
film elements, providing detailed insight into cellular-
macromolecule interplay. The OprF localized in the cell
and OMVs, together with lectin LecB, is involved in the
attachment process. Both proteins condition the tissue-
bacteria/OMV adhesion, the formation of the bacteria-
bacteria/OMV complex, as well as bacterial/OMV-poly-
saccharide interactions in the matrix. It is also proposed
that OMVs bearing OprF are a decoy to sequestrate
neutrophil elastase thus protecting sessile cells from
the innate immune-mediated lysis [28].
Lipids
Lipids as a component of glycolipids, sphingolipids, tei-
choic acids (wall teichoic acids, WTA, and lipoteichoic
acids, LTA) and mycolic acids build the bacterial cell wall
structure, and therefore are also found in the biofilm
matrix when released from lysed cells. As most of them
are long-chain hydrophobic molecules they enhance the
autoaggregation of bacteria hidden in the biofilm and
trigger the attachment/adhesion process, especially to
abiotic surfaces [29].
OMVs and MVs
Outer membrane vesicles (OMVs) produced by Gram-
negative bacteria are a sophisticated weapon used for
different physiological and pathogenesic purposes. These
lipoprotein vesicles, produced under the control of quo-
rum-sensing systems, are released in response to environ-
mental stress. Bacteria use OMVs to transfer specific
cargos to distant places. These vesicles, mimicking the
original bacterial cell, serve as a bait for antibodies,
antimicrobial peptides, or lytic phages, and induce apo-
ptosis and inflammation, and attract immune response
away from its producer. OMVs carrying QS molecules,
antibiotic degrading enzymes, DNA, or specific toxins to
defeat competitive microorganisms, are important for
HGT, interspecies interactions, or communication. The
strategy to utilize OMVs enables both the planktonic orCurrent Opinion in Biotechnology 2021, 68:251–261 sessile style of life [30]. OMVs containing lytic enzymes
enhance the release of eDNA into the matrix providing
the material for the biofilm spatial structure. Recent
studies provide interesting data on the OMVs role in
biofilm formation and maintenance as well, and show that
the composition of biofilm- and planktonic-derived vesi-
cles differ in terms of glycoproteins and lipids [28,31].
The P. aeruginosa vesiculation process consumes the
hydrophilic B-band LPS for OMV formation leaving
bacteria enriched in the hydrophobic A-band LPS. Simul-
taneously, the isomerization of cis- into trans- unsaturated
fatty acids in the inner membrane is observed. Both
mechanisms make the cell surface more hydrophobic
and the membrane more rigid which make bacteria prone
to self-aggregation. It was found that hypoxia forces
bacteria towards intensive OMV production, thus induc-
ing biofilm and microcolony formation. This suggests that
the vesiculation process, at least in an intensive biofilm
producer P. aeruginosa, is in some way a self-featured
process driven by the low oxygen conditions prevailing
within the biofilm milieu [31]. In other words, this mech-
anism allows for fast transformation of bacteria from
planktonic to biofilm residents by a rapid increase in cell
surface hydrophobicity due to the release of OMVs.
Bacterial cell lysis, caused by phage propagation, lytic
enzymes, or other external agents, enriches the EPS with
membrane vesicles (MV) as cell leftovers, which further
serve as a source of nutrients, DNA pool in the matrix, and
analogously to OMVs which may also be targeted as a
decoy by the immune system or phages.
Crystallines
The biofilm structure may be stabilized and solidified by
inorganic components forming crystallines. Common uri-
nary tract pathogens including Proteus species, Morganella
morganii, Klebsiella pneumoniae, P. aeruginosa, and staphy-
lococci, produce urease-triggering external pH. That
leads to the biomineralization of CaCO3 and the forma-
tion of insoluble crystals. The accumulation of mineral
crystals can be usually seen on abiotic surfaces, such as
plastic urethral catheters in biofilm-borne infections. The
presence of crystalline calcite was also observed in Gram-
positive bacteria, such as Bacillus subtilis and Mycobacte-
rium smegmatis, which suggests it being a common biofilm
feature. The mineral crystallines interact with the
remaining organic structural components of EPS, espe-
cially those of negative charge, further stabilizing, and
fixing, the whole biofilm structure to a particular surface
[32].
Recent studies revealed another type of crystal-like par-
ticle formed in the biofilm milieu. It was found that
filamentous prophage Pf4 is induced and released by
sessile living P. aeruginosa cells, and by interaction with
the extracellular matrix assembly forms liquid crystalline
droplets [33]. These droplets are accumulated around thewww.sciencedirect.com
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bacteria from the external harsh environment, antibiotics,
and the immune system attack. As the filamentous ino-
viruses are commonly found prophages it is proposed that
the formation of organic crystalline liquid is a wide-spread
strategy utilized by many biofilm-forming bacteria [34].
Phage features used in biofilm control
The ubiquitous nature of biofilms indicates that interac-
tions between matrix-embedded bacteria and phages
have certainly been frequent throughout evolutionary
history. Consequently, phages and biofilm communities
have found many mechanisms of coexistence that remain
poorly understood. The protective effect of the biofilm
matrix and the physiology of biofilm-living cells are,
among other factors, responsible for repressing phage
predation. The biofilm density plays an important role
in phage/biofilm interaction; when biofilms are sparse,
phage/bacteria encounters are less likely to occur, result-
ing in poor infection efficiency. On the other hand, the
success of phage dispersion in dense EPS relies on its
mobility [35]. Therefore, phages have developed specific
strategies to penetrate the three-dimensional structure of
the biofilm, and to cope with different cell physiologies
(Figure 1).
Diffusion through biofilm water-channels
Biofilms are highly hydrated structures formed by voids,
also called water channels, that help the diffusion of
nutrients throughout the biofilm. Phages can diffuse
through these void spaces and penetrate the inner biofilm
layers by diffusion through gravity. In contrast to anti-
biotics, where diffusional limitations lead to a depletion of
the antibiotic concentration at the inner biofilm layers,
phages increase in number due to active replication. This
fact leads to the lysis of a fraction of the sessile population
inhabiting the inner layers, contributing to the distur-
bance of the biofilm 3D structure [36] (Figure 2).
Enzymatic degradation
Phages are naturally adapted to penetrate biofilm EPS
and are equipped with specific enzymes such as
VAPGHs, endolysins, and depolymerases which potenti-
ate their anti-biofilm killing efficacy. VAPGHs and endo-
lysins destroy the bacteria cell wall whereas depoly-
merases are capable of degrading the bacterial surface
polysaccharides as well as the EPS components [38].
There is evidence that some phages may even induce
depolymerase enzyme expression, however, it is still
unclear if this process is controlled at the phage level
or as the bacterial response to phage predation [39]. It is
important to mention that the cell lysis itself, caused by
phage propagation, leads to the release of bacterial cell
content directly into the biofilm milieu, thus bacterial
enzymes responsible for extracellular polymers resorption
and biofilm dispersion are also brought into the EPS
degradation action.www.sciencedirect.com Hitchhiking on carrier bacteria
Phages can absorb reversibly to the appendices of motile
bacteria. This feature has been shown to occur with
phages infecting Caulobacter crescentus, where the first
interaction with the bacterial flagellum takes place
through a filament on the phage head [40]. Therefore
phages may develop an active way of penetrating inside
biofilm, hitchhiking on motile carrier bacteria.
Tackling persister cells
Unlike antibiotics, phages can infect and kill dormant and
persister cells (Figure 1b). Persister cells can be protected
from temperate phages (by superinfection immunity),
however, they are not protected from strictly lytic infec-
tion. Data show that phages can replicate in late stationary
cultures known to be mainly composed of growth
arrested-cells. The process of replication can initiate
immediately, in some cases, after phages enter the target
cell [41], or as soon as cells restore their normal growth
[42]. Furthermore, the release of intracellular material,
and the dispersion of the biofilm, triggers the metabolism
of the persister population further activating phage
replication.
Strategies to improve phage efficacy
Despite the strategies used by phages to counteract the
defensive mechanisms of biofilms, native phages, per se,
are not able to eradicate the entire biofilm population. To
circumvent phage limitations and improve their perfor-
mance for efficient biofilm control, different approaches
have been perused, such as combined therapy (discussed
later), or genetic manipulation.
It is important to highlight the potential of synthetic
biology tools to rebuild phage genomes displaying
enhanced biological properties [43]. Several genome
engineering tools have been efficiently applied to
phages [44]. It is worth mentioning the recently devel-
oped platform for rebooting phages of gram-positive
bacteria using Listeria-L-form cells as rebooting com-
partments [45]. These tools can be particularly useful in
the design of engineered phages equipped with matrix-
degrading enzymes. Nevertheless, there are still many
obstacles in this area such as the incorporation of large
gene fragments, for example those encoding depoly-
merases, into a phage genome. Thus the overall genome
size limitation requires the elimination of other genes.
However, the decision of the best gene-editing strategy
is still a blind operation caused by deficient knowledge
of many phage genes function, and their influence on
the bacterial host.
Phage derived enzymes
Endolysins and virion-associated peptidoglycan
hydrolases
Phage lytic proteins, such as endolysins and virion-asso-
ciated peptidoglycan hydrolases (VAPGHs) have highCurrent Opinion in Biotechnology 2021, 68:251–261
256 Nanobiotechnology - phage therapy
Figure 2
(a) (b)
Non-infected biofilms Phage infected biofilms
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Microscope images of P. aeruginosa PAO1 phage-infected biofilm. Forty-eight-hour phage-free biofilm (a), biofilm exposed to a P. aeruginosa
infecting phage for 5 min (b). The green fluorescence corresponds to P. aeruginosa cells and the red fluorescence is P. aeruginosa phage infected
cells. Images were obtained using the LNA-FISH technique, in which two probes were used; the green fluorescence probe targets the rRNA 23S
and the red fluorescence probe targets the mRNA encoding for the major capsid protein of the phages. The images are adapted from Ref. [37].antimicrobial activity against Gram-positive bacteria
when added externally, due to their ability to hydrolyse
the peptidoglycan (PG) from the cell wall (Figure 1b)
[46,47]. Phages can produce a wide range of PG-degrad-
ing enzymes including muramidase, transglycosylase,
glucosaminidase, amidase, and endopeptidase. The two
latter enzymes are also classified as proteases. Endolysins
from Gram-positive infecting phages have a modular
design with catalytic activity and substrate recognition
separated into two distinct types of functional domains
(cell wall binding domains (CBDs) and enzymatically
active domains (EADs)). This modularity facilitates
domain engineering and production of chimeric enzymes
by fusion of catalytic or binding domains from different
lytic enzymes, thereby altering enzymatic properties [48].
The application of endolysins against Gram-negative
pathogens is impaired by the presence of a protecting
outer membrane (OM) layer, however, the combination
with membrane permeabilizers turned out to significantly
improve lysin efficiency. More recently, genetic engi-
neering allowed us to design the lysin/cationic peptide
combination called Artilysins [49]; the lysin/bacteriocin
version to obtain Lysocins [50], and the lysin/phage
receptor binding proteins to generate Innolysins, as an
anticipated promising strategy [51].
In terms of anti-biofilm activity, phage lytic proteins offer
interesting properties, for example, they easily penetrateCurrent Opinion in Biotechnology 2021, 68:251–261 the biofilms [52] and are active against both low metabol-
ically active cells and persister cells [53]. Besides these,
other valuable antimicrobial characteristics include (i) the
lack of resistance development to phage lytic proteins, as
peptidoglycan is the crucial and conservative structure;
(ii) the lysin activity spectrum is usually broader than the
phage host range but narrower than antibiotics/disinfec-
tants); (iii) a simple lysin structure is suitable for modifi-
cation using synthetic biology tools [54].
The ability of phage lytic proteins to remove biofilms
formed by Gram-positive bacteria such as S. aureus
[55,56], Streptococcus pneumoniae [57,58] and Listeria
monocytogenes [59] has been confirmed in vitro. Moreover,
looking at a future application in human therapy, several
endolysins have been probed to also be effective in vivo
using animal models [60].
Notable progress has been made in removing biofilms
formed by Gram-negative bacteria, thanks to the study of
endolysins with interesting properties. For example,
some endolysins are endowed with highly positively
charged C-terminal peptides, which can kill bacteria by
disrupting the bacterial cytoplasmic membrane [61];
additionally, thermostable endolysins with broad antimi-
crobial activity, in combination with weak acids, could be
useful as an antimicrobial product to control important
pathogens such as Salmonella or P. aeruginosa [62].www.sciencedirect.com
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effect beyond their lytic activity, as sub-inhibitory concen-
tration downregulated genes, encoding different proteins
with autolytic activity, which result in diminished biofilm
formation [63]. Indeed, complementary to biofilm removal,
phage-derived lysins can be useful for the inhibition of
biofilm development, especially on surgical implants and
other medical equipment to avoid bacterial colonization.
Manufacturing antimicrobial surfaces coated with endoly-
sins and matrix-degrading enzymes is possible to obtain new
materials, for example, bioengineered spider silk intended
for drug-free sutures for reducing post-implantation infec-
tions [64]. All this evidencehas led to propose phage lysins as
novel antimicrobials to be used in the clinic, and as disin-
fectants for application in various branches of the economy
such as the food industry [65].
Tail-associated proteins with exopolysaccharide
degrading activity
Some phages also encode tail-associated proteins with
exopolysaccharide degrading activity (depolymerases),
and are able to digest polysaccharide forming capsules,
lipopolysaccharide, or extracellular polymeric material
from the biofilm matrix, conferring the phage with the
ability of biofilm invasion and dispersion and, therefore,
with potential to be used for biofilm removal (Figure 1b)
[39,47]. The data concerning the biofilm dispersion medi-
ated by these proteins is still scarce. Several enzymes with
endosialidase, hydrolase, or lyase activity have been
identified, mostly in phages infecting Gram-negative
bacteria, and only a few in those infecting Gram-positive
bacteria [66]. Recombinant depolymerase-targeting cap-
sules have been shown to significantly inhibit biofilm
formation and degrade mature biofilm from important
pathogens such as K. pneumoniae [7,67] or S. aureus [68].
The O-specific polysaccharide lyase cleaving B-band LPS
of P. aeruginosa was proved to effectively reduce the
biofilm mass by targeting both bacterial cells and OMVs
embedded in the matrix milieu [69]. Another interesting
enzyme (hyaluronidase) is encoded by streptococcal pro-
phages to degrade capsular hyaluronic acid and to reduce
biofilm matrix viscosity. Moreover, lysogenic streptococci
utilize these prophage-encoded enzymes as a virulence
factor, digesting the main component of the tissue extra-
cellular matrix [70].
Similar to endolysins, the antibiofilm activity of these
proteins could be enhanced when used in combination
with antibiotics, which may represent a promising strat-
egy to combat infections caused by drug-resistant and
biofilm-forming pathogens. By degrading the bacterial
capsule, depolymerases exhibit an anti-virulent mode
of action enhancing the innate immune response [71].
Moreover, a reduction of in vivo virulence, along with a
significant decrease in the levels of proinflammatory
cytokines mediated by treatment with depolymerase
enzymes, has been demonstrated in animal models ofwww.sciencedirect.com bacterial infection [72]. Remarkably, in some reports, the
exposure of bacterial cultures to phage depolymerase
does not promote the development of bacteria refractory
to these activities [73].
Other phage-derived enzymes
Phage derived DNases are usually associated with pro-
phages or prophage-like elements and represent a close
evolutionary relationship between bacterial hosts and
temperate phages. Streptococcal prophage-encoded
DNAses, considered as important virulence factors, are
utilized by bacteria to degrade neutrophil extracellular
traps and escape the innate immune response [74]. More-
over, these proteins seem to be involved in streptococcal
biofilm EPS dispersion, as well as removing biofilms of
competitive commensal bacteria inhabiting the same
ecological niche (Figure 1b).
Lipases are among other useful enzymes to disperse
biofilms by disrupting the lipidic bounds involved in
cell-cell or cell-surface interaction. There is little infor-
mation about the existence of lipid hydrolysis activity in
phages, and in fact, lipases represent rare domains found
within phage structural components. Nevertheless, a
Lipase_GDSL_3 domain has been found in the depoly-
merases of Cellulophaga phages [39]. Moreover, SGNH
hydrolases were found in conserved domains of Phietalike
viruses within the Siphoviridae family. Although enzymes
containing this domain have little sequence homology to
true lipases, they are involved in the hydrolysis of fatty
acids and aromatic esters [75].
Mycobacteria have a specific cell wall structure with the
mycomembrane composed of a mycolyl-arabinogalactan-
peptidoglycan complex (mAGP). Therefore mycobacter-
iophages are provided with two types of cell wall hydro-
lytic enzymes, LysA (PG hydrolase, discussed above as
endolysin) and LysB (mycolylarabinogalactan esterase).
The latter is essential for the disruption of mycomem-
brane by cleaving the ester bond between the arabino-
galactan and mycolic acids in the mAGP. LysB is struc-
turally recognised as esterase, cutinase, or lipase and is
able to degrade a wide panel of different fatty acids (C4–
C16) [76]. The LysB, as lipolytic enzymes, showed anti-
bacterial activity when combined with outer membrane
permeabilizers [77].
Overall, the identification of antibiofilm properties of
phage-derived proteins requires the use of rapid, repro-
ducible, and accurate technology for screening and com-
paring their effectiveness. A method based on impedance
measurement, using xCelligence real-time cell analyzer
(RTCA) equipment [78], and a quartz tuning fork (QTF)
system as impedance sensors [79], were validated to
monitor biofilm formation and disruption in different
bacterial species.Current Opinion in Biotechnology 2021, 68:251–261
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Generally, the susceptibility of biofilms to phages and
phage-borne enzymes is dependent on biofilm complex-
ity, strain sensitivity, and the biofilm maturation stage. As
a consequence, the complete removal of total biomass
(adhered cells plus extracellular material) is difficult.
Therefore, biofilm eradication might be achieved using
a combined treatment as it has been shown that phages
and enzymes can be effectively used in cocktails, with
antibiotics, and other antimicrobial chemicals [7,12,80]
The application of phages/lysins with antibiotics, simul-
taneously or sequentially, has been revealed as particu-
larly effective against biofilms. Indeed, antibiotics can
kill the rapidly growing cells (young biofilms) whereas
lysins also target stationary phase cells (old biofilms).
Synergism occurs because phage-associated bacterial
lysis releases the nutrients reactivating the metabolic
activity of the growth-arrested cells, that further become
sensitive to antibiotics. Lysis also causes a dispersion of
the EPS, enhancing the diffusion of the antibiotic to the
inner matrix layers, whereas the oxygen availability
increases the drug activity [8]. In some cases, phage-
resistant cells might be more susceptible to antibiotics
[9]. In turn, phages can infect a drug-resistant population,
overcoming one of the major limitations of common
therapy.
The combined use of phages and matrix dispersing
agents is also shown to be very effective. Polysaccha-
ride-degrading enzymes or DNases, whatever the ori-
gin, can efficiently break down the biofilm matrix,
enhancing the penetration of phages and chemicals,
particularly in dense biofilms. Thus the possible appli-
cation of phage-borne enzymes which are active against
EPS components might significantly  improve the anti-
biofilm efficiency of both antibiotics and phages. The
use of mechanical debridement improves phage infec-
tion as a consequence of better phage and drug accessi-
bility to the biofilm cells (Figure 1b). Moreover, cells
released due to debridement also become more suscep-
tible to the treatment. This approach, followed by
phage application, has been successfully used in the
treatment of chronic wounds [10].
Final considerations and future perspectives
The complex structure of biofilm, encompassing a broad
biodiversity of inhabitants, specific niches, cell-to-cell
interactions, oxygen, and nutrients at different concen-
trations, as well as a panel of extracellular macromolecule-
stabilizing biofilm conglomerate, present us with a huge
challenge in developing effective tools for its eradication.
To design improved phage-based methods to remove
biofilms, it is important to deepen knowledge in the
specific characteristics of biofilms that may play a role
in the penetration, diffusion, and propagation of phages
through the biofilm. For example, penetration of mixedCurrent Opinion in Biotechnology 2021, 68:251–261 biofilms is largely dependent on the specific bacterium or
combination of bacteria [81] and on phage morphology
[82]. Additionally, bacteria-phage dynamics in biofilms
promotes the coexistence of phage-susceptible and
phage-resistant bacteria due to the susceptible cell cluster
protection by the phage-resistant bacteria layer [11].
Therefore, it seems reasonable to aim to use phages
(natural bacterial partners) to learn what kind of weapon
or strategies have been evolutionarily developed to suc-
cessfully infect and invade bacterial populations, espe-
cially those hidden and protected by the biofilm structure
(Figure 1a). Phages are natural toolboxes offering an
arsenal of phage-borne enzymes that can be better
exploited as biofilm dispersing agents (Figure 1b). On
the other hand, phages harbour genetic determinants that
interfere with the host physiology, which could also be
explored to target sessile and dormant or persistent cells.
Furthermore, we may gear bacterial viruses, both natural
or engineered, for efficient infection, bacterial lysis, or
physiology modification.
With the modern tools and technologies provided by
synthetic biology, and widely available high-throughput
sequence techniques, we can look for potential genes and
natural systems to design modified, and more effective,
antibiofilm agents and complex therapies.
However, we have to keep in mind the possible limita-
tions of future antibiofilm approaches. It is inevitable
that bacteria put under selective pressure will find a way
to escape novel antibacterials and will develop new types
of resistance mechanisms. Nevertheless, evolution has
taught us that a constant arms race is an indispensable
element of development and progress, in all kinds of
aspects of life. The biofilm biology itself has been not
fully elucidated yet, hence, the mechanism of intercel-
lular interactions and complex phage-bacteria interplay
needs to be deeply explored and understood to ensure
the successful progress of the future antibiofilm
therapies.
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